Published in Mayo Clin Proc on April 01, 2006
Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol (2008) 1.11
A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc (2009) 1.10
Combination drug therapy for chronic pain: a call for more clinical studies. J Pain (2010) 0.94
Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag (2011) 0.87
Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence (2011) 0.87
Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med (2012) 0.82
A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res (2009) 0.82
Electroacupuncture to treat painful diabetic neuropathy: study protocol for a three-armed, randomized, controlled pilot trial. Trials (2013) 0.81
MR-guided focused ultrasound: a new generation treatment of Parkinson's disease, essential tremor and neuropathic pain. Interv Neuroradiol (2014) 0.79
Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol (2010) 0.77
Use of select medications prior to duloxetine initiation among commercially-insured patients. J Pain Res (2012) 0.77
Pain associated with diabetic peripheral neuropathy: a review of available treatments. P T (2008) 0.76
Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain. Curr Drug Targets (2016) 0.76
Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag (2015) 0.75
Managing Chronic Pain in Patients with Opioid Dependence. Curr Treat Options Psychiatry (2014) 0.75
The effect of Neuragen PN on neuropathic pain: A randomized, double blind, placebo controlled clinical trial. BMC Complement Altern Med (2010) 0.75
Pharmacological treatment of diabetic peripheral neuropathy. P T (2015) 0.75
Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain (2009) 9.36
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol (2003) 3.80
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ (2010) 3.46
Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2007) 3.26
Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain (2006) 2.51
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain (2004) 2.34
Classification of patients with pain based on neuropathic pain symptoms: comparison of an artificial neural network against an established scoring system. Eur J Pain (2006) 2.09
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain (2007) 2.07
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Development of a neuropathic pain questionnaire. Clin J Pain (2003) 1.96
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain (2012) 1.88
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Aphasic or amnesic status epilepticus detected on PET but not EEG. Epilepsia (2008) 1.81
Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology (2008) 1.65
A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain (2009) 1.64
The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain (2006) 1.59
Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol (2006) 1.59
Abnormal contralateral pain responses from an intradermal injection of phenylephrine in a subset of patients with complex regional pain syndrome (CRPS). Pain (2004) 1.55
Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain (2015) 1.55
Recognition and management of diabetic neuropathy. Prim Care (2007) 1.51
The science of fibromyalgia. Mayo Clin Proc (2011) 1.47
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol (2007) 1.47
Dietary fat and protein interact in suppressing neuropathic pain-related disorders following a partial sciatic ligation injury in rats. Pain (2004) 1.43
Perceived controllability modulates the neural response to pain. J Neurosci (2004) 1.41
Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg (2006) 1.40
Do pain specialists meet the needs of the referring physician? A survey of primary care providers. J Opioid Manag (2008) 1.39
Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc (2006) 1.35
Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc (2011) 1.33
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett (2006) 1.33
New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res (2006) 1.30
Individual differences in the effects of perceived controllability on pain perception: critical role of the prefrontal cortex. J Cogn Neurosci (2007) 1.30
Sympathetic sprouting and changes in nociceptive sensory innervation in the glabrous skin of the rat hind paw following partial peripheral nerve injury. J Comp Neurol (2006) 1.25
Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol (2011) 1.24
Hypolocomotion, asymmetrically directed behaviors (licking, lifting, flinching, and shaking) and dynamic weight bearing (gait) changes are not measures of neuropathic pain in mice. Mol Pain (2010) 1.18
Assessment of neuropathic pain in primary care. Am J Med (2009) 1.14
Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol (2011) 1.11
Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain (2012) 1.11
Quantitative sensory testing and mapping: a review of nonautomated quantitative methods for examination of the patient with neuropathic pain. Clin J Pain (2009) 1.07
Norepinephrine-induced nociception and vasoconstrictor hypersensitivity in rats with chronic post-ischemia pain. Pain (2008) 1.07
Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med (2011) 1.05
A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology. Pain Med (2010) 1.02
Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med (2008) 1.01
Pain coping strategies play a role in the persistence of pain in post-herpetic neuralgia. Pain (2003) 1.01
A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain (2006) 0.99
Persistent low-frequency spontaneous discharge in A-fiber and C-fiber primary afferent neurons during an inflammatory pain condition. Anesthesiology (2007) 0.98
Painful physical symptoms in depression: a clinical challenge. Pain Med (2007) 0.98
Cutaneous tactile allodynia associated with microvascular dysfunction in muscle. Mol Pain (2008) 0.93
The cognitive effects of opioids. Pain Manag Nurs (2004) 0.93
Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J Immunol Methods (2010) 0.90
Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood (2005) 0.90
Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc (2011) 0.89
Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology (2011) 0.89
Analgesic treatment for moderate-to-severe acute pain in the United States: patients' perspectives in the Physicians Partnering Against Pain (P3) survey. J Opioid Manag (2011) 0.89
Older and younger adults in pain management programs in the United States: differences and similarities. Pain Med (2006) 0.89
Are alcoholism treatments effective? The Project MATCH data. BMC Public Health (2005) 0.88
Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med (2007) 0.88
Imaging studies in Freund's complete adjuvant model of regional polyarthritis, a model suitable for the study of pain mechanisms, in the rat. Arthritis Rheum (2011) 0.88
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. Transplantation (2008) 0.86
CNS mastitis: nothing to worry about? Vet Microbiol (2008) 0.85
Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf (2009) 0.85
The effect of recombinant IgG antibodies against the leucine-33 form of the platelet beta3 integrin (HPA-1a) on platelet function. Thromb Haemost (2004) 0.85
Characterization of a model of cutaneous inflammatory pain produced by an ultraviolet irradiation-evoked sterile injury in the rat. J Neurosci Methods (2005) 0.84
Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manage (2012) 0.84
Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med (2014) 0.84
Neuropathic pain: a crisis of definition? Anesth Analg (2003) 0.83
Pain ratings at the thresholds are necessary for interpretation of quantitative sensory testing. Muscle Nerve (2005) 0.83
A behaviorist perspective. Adv Psychosom Med (2011) 0.83
A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J Pain (2002) 0.83
Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy. J Pharmacol Sci (2008) 0.82
Effects of tourniquet ischemia on current perception thresholds in healthy volunteers. Pain Pract (2002) 0.82
Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. A 6-month follow-up study. Cancer (2003) 0.80
Unpleasant odors increase pain processing in a patient with neuropathic pain: psychophysical and fMRI investigation. Pain (2005) 0.80
What variables are associated with an expressed wish to kill a doctor in community and injured patient samples? J Clin Psychol Med Settings (2010) 0.80
Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-inflammatory therapy. Eur J Immunol (2005) 0.79
The need for chronic opioids to treat persistent noncancer pain. Gen Hosp Psychiatry (2011) 0.79
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. Expert Opin Pharmacother (2012) 0.79
Commentary: physical approaches for the treatment of epilepsy: electrical and magnetic stimulation and cooling. Neurotherapeutics (2009) 0.79
The opioid treatment agreement: a real-world perspective. Am J Bioeth (2010) 0.78
Novel therapies for the control and prevention of neuropathic pain. Neurotherapeutics (2009) 0.78
Effects of non-uniform static magnetic fields on the rate of myosin phosphorylation. Bioelectromagnetics (2002) 0.78
Introduction. Pain and the elderly. Clin J Pain (2004) 0.78
Relationships between functional capacity measures and baseline psychological measures in chronic pain patients. J Occup Rehabil (2003) 0.78
Hysterical paralysis: a report of three cases and a review of the literature. Spine (Phila Pa 1976) (2003) 0.78
Management of chronic noncancer pain in depressed patients. Postgrad Med (2011) 0.77
Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain. J Pain (2013) 0.77
Analgesic effects of antidepressants. J Clin Psychiatry (2003) 0.77
Clinical features of epilepsy in patients with cerebellar structural abnormalities in a referral center. Epilepsy Res (2007) 0.77
Quantification of the effects of antibodies on the extra- and intracellular dynamics of Salmonella enterica. J R Soc Interface (2012) 0.77
Integrating health information technology and electronic health records into the management of fibromyalgia. Postgrad Med (2013) 0.77
Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets. Eur J Immunol (2014) 0.77